Protagonist Therapeutics: UBS initiates coverage with buy rating and $184 target price
PTGX•UBS initiated coverage of Protagonist Therapeutics with a buy rating and a target price of $184.
Related News
Consolidated Water unit wins $39.8 million Pismo Beach water-treatment design-build contract
CWCO•
US stocks muted on Columbus Day
SPY•
BioAge Labs, Inc.: UBS initiates coverage with neutral rating and $8 target price
BIOA•
Tectonic Therapeutic initiates coverage with neutral rating and $26 target price
TECX•
Oil surge keeps S&P 500, Nasdaq in check before earnings; Salesforce lifts Dow
SPY•